Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 20, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Lyophilized Injectable Market Predicted to Reach USD 5 billion by 2031, Registering at a 5% CAGR | Exclusive Report by Transparency Market Research
August 29, 2023 07:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global market for lyophilized injectable is anticipated to advance with almost a 5%...
Lindora taps retail and health industry veteran Colleen Lewis as new CEO, announces new metabolic health services
July 18, 2023 09:15 ET
|
Lindora Clinic
IRVINE, July 18, 2023 (GLOBE NEWSWIRE) -- Lindora Clinic, a leading weight management and metabolic health company, today announced the appointment of Colleen Lewis as its chief executive officer...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023 06:57 ET
|
Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 15, 2022 19:01 ET
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.
May 24, 2022 10:39 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
March 08, 2022 02:00 ET
|
INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
March 08, 2022 02:00 ET
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Global Artificial Intelligence (AI) in Drug Discovery Market ($4197.5 Mn by 2028) Growth Forecast at 41.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
March 03, 2022 04:49 ET
|
Vantage Market Research
WASHINGTON, March 03, 2022 (GLOBE NEWSWIRE) -- The Global Artificial Intelligence in Drug Discovery Market size is expected to reach USD 4,197.5 Million by 2028, exhibiting a Compound Annual Growth...